Neutralizing anti-interferon-α antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (α2a) and lymphoblastoid interferon-α

British Journal of Haematology

Volumn 94, Issue 2, 1996, Pages 300-305

  Russo, Domenico ^a   Candoni, Anna ^a   Zuffa, Eliana ^b   Minisini, Rosalba ^a   Silvestri, Federico ^a   Fanin, Renato ^a   Zaja, Francesco ^a   Martinelli, Giovanni ^b   Tura, Sante ^b   Botta, Giuseppe ^a   Baccarani, Michele ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

CML; IFN ; neutralizing antibodies

Indexed keywords

ALPHAN1 INTERFERON; INTERFERON ANTIBODY; LYMPHOBLAST INTERFERON; NEUTRALIZING ANTIBODY; RECOMBINANT ALPHA2A INTERFERON;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ANTIBODY TITER; CLINICAL ARTICLE; LEUKOCYTE COUNT; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; YOUNG ADULT;

EID: 8944249778     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1790.x     Document Type: Article

References (23)

1. Aitchinson, R., Allen, P., Schey, S. & Newland, A.C. (1991) Antiinterferon antibodies in alpha interferon treated patients with chronic myeloid leukaemia. British Journal of Haematology, 78, 465-467.
2. Allan, N.C., Richards, S.M., Sheperd, P.C.A., on behalf of the UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemias (1995) UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet, 345, 1392-1397.
3. Arthur, C.K. & Ma, D.D.F. (1993) Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukaemia. Acta Haematologica, 89, (Suppl. 1). 15-21.
4. Antonelli, G., Giannelli, G., Pistello, M., Maggi, F., Vatteroni, L., Currenti, M., Del Vecchio, S., Roffi, L., Pastore, G. & Dianzani, F. (1994) Clinical significance of recombinant interferon-α2 neutralizing antibodies in hepatitis patients. Journal of Interferon Research. 14, 211-213.
5. Dianzani, F., Antonelli, G., Amicucci, P., Cefaro, A. & Pintus, C. (1989) Low incidence of neutralizing antibody formation to interferon-α2b in human recipients. Journal of Interferon Research, 9. (Suppl. 1). S33-S36.
6. Freund, M., Von Wussow, P., Diedrich, H., Eisert, R., Link, H., Wilke, H., Buchholz, F., LeBlanc, S., Fonatsch, C., Deicher, H. & Poliwoda, H. (1989) Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. British Journal of Haematology. 72, 350-356.
7. Galton, J.E., Bedford, P., Scott, J.E., Brand, C.M. & Nethersell, A.B.W. (1989) Antibodies to lymphoblastoid interferon. Lancet, ii. 572-573.
8. + chronic myeloid leukemia (CMI.): preliminary cytogenetic results, Leukemia and Lymphoma, 11. (Suppl. 1), 181-183.
9. + chronic myeloid leukaemia: clinical and cytogenetic results at 2 years in 322 patients. Haematologica, 77, 204-214.
10. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New England Journal of Medicine, 330, 820-825.
11. Kantarjian, H.M., Keating, M.J., Estey, E.H., O'Brien, S., Pierce, S., Beran, M., Koller, C., Feldman, E. & Talpaz, M. (1992) Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-α and low-dose cytarabine. Journal of Clinical Oncology, 10, 772-778
12. Kantarjian, H.M., Smith, T.L., O'Brien, S., Beran, M., Pierce, S., Talpaz, M., and the Leukemia Service (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Annals of Internal Medicine. 122, 254-261.
13. Moormeier, J.A., Westbrook, C.A., Ratain, M.J. & Golomb, H.M. (1989) Interferon alfa-2b antibodies and clinical resistance in a patient with hairy cell leukemia. Leukemia and Lymphoma, 1.43-45.
14. Öberg, K.E. (1994) Autoimmunity and antibodies to interferons in patients with carcinoid tumors: clinical consequences. Journal of Interferon Research, 14, 215-216.
15. Steis, R.G. & Longo, D.L. (1994) Clinical relevance of recombinant interferon-α2a antibodies in patients with hairy cell leukemia. Journal of Interferon Research, 14, 207-209.
16. Steis, R.G., Smith, J.W., Urba, W.J., Clark, J.W., Itri, L.M., Evans, L.M., Schoenberger, C. & Longo, D.L. (1988) Resistance to recombinant interferon alfa-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. New England Journal of Medicine, 318, 1409-1415.
17. Suk-Fong Lok, A., Lai, C-L. & Leung, E.K.-Y. (1990) Interferon antibodies may negate the antiviral effects of recombinant α-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology, 12, 1266-1270.
18. Talpaz, M., Kantarjian, H., Kurzrock, R., Trujillo, J.M. & Gutterman, J.U. (1991) Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients. Annals of Internal Medicine, 114, 532-538.
19. Talpaz, M., McCredie, K.B., Mavligit, G.M. & Gutterman, J.U. (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood, 62, 689-692.
20. Von Wussow, P.V., Helmann, R., Hochhaus, T., Jakschies, D., Nole, K.U., Prummer, O., Ansari, H., Hasford, J., Heimpel, H. & Deicher, H. (1994) Roferon (rIFN-α2a) is more immunogenic than Intron A (rIFNα-2b) in patients with chronic myelogenous leukemia. Journal of Interferon Research, 14, 217-219.
21. Von Wussow, P.V., Hehlmann, R., Nolte, K.U., Jakschies, D., Hochhaus, T., Witte, T., Ansari, H., Hasford, J., Prummer, O., Heimpel, H. & Deicher, H. (1993) rIFN-n2A (Roferon) is more immunogenic than rIFN-α2B (Intron A) in patients with CML. Blood. 82, (Suppl. 1). Abstract 1496.
22. Von Wussow, P., Jakschies, D., Freund, M. & Deicher, H. (1989) Humoral response to recombinant Interferon α2b in patients receiving recombinant interferon-α2b therapy. Journal of Interferon Research, 9, (Suppl. 1), 525-531.
23. Von Wussow, P.V., Jakschies, D., Freund, M., Hehlmann, H., Brockhaus, F., Hochkeppel, H., Horisberger, M. & Deicher, H. (1991) Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. British Journal of Haematology, 78, 210-216.